News

VC-backed Verve Therapeutics expands scientific advisory board with new addition

Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Geall to its scientific advisory board. Geall is vice president of formulations, analytics and chemistry at Avidity Biosciences. Verve's backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.

Miami’s venture ecosystem is trying hard to grow up

South Florida has an active first half, with VC activity already surpassing all of last year for the Miami metro area.

Friday Letter: How Tim Smith of Bee Partners helps founders

A weekly letter from the VCJ editor about an assortment of what's happening in VC, along with who we're meeting and what we're hearing

In Canada, 11 percent of H1 VC investments go to agriculture

Protectionism and increased scrutiny of foreign investment into the US encourage investors to look at Canada, as appetite for direct institutional investment also grows.

Pre-seed-focused Bee Partners closes third fund, promotes Tim Smith to partner

Former Disney execs look for hit with Smash Ventures

AV8's partners discuss their growing firm, strategy and being backed by Allianz

VC and technologist Xiang Lin presumed dead in Labor Day diving boat fire

Former Lionsgate exec is officially fundraising for new game-focused venture

San Francisco accelerator Heavybit raises its first venture fund